Watching for data release
$Lipocine(LPCN.US$ Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, Lpcn 1154. Lipocine Inc: Topline Results Anticipated Late in 2Q 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
TrytosaveabitOP : Lipocine: Confirmed With FDA Acceptance of Proposal for Nda Filing Enabled by Pivotal Pk Study Comparing Exposure of Lpcn 1154 With IV Infusion of Brexanolone